Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies
Open Access
- 3 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Stem Cell Research & Therapy
- Vol. 11 (1), 1-10
- https://doi.org/10.1186/s13287-020-01730-7
Abstract
Multiple studies have reported that mesenchymal stem cell (MSC) therapy has beneficial effects in experimental models of sepsis. However, this finding remains inconclusive. This study was performed to systematically determine the connection between MSC therapy and mortality in sepsis animal models by pooling and analyzing data from newly published studies. A detailed search of related studies from 2009 to 2019 was conducted in four databases, including MEDLINE, EMBASE, Cochrane Library, and Web of Science. After browsing and filtering out articles that met the inclusion criteria for statistical analysis, the inverse variance method of the fixed effects model was used to calculate the pooled odds ratios (ORs) and their 95% confidence intervals (CIs). Twenty-nine animal studies, including 1266 animals, were identified. None of the studies was judged to have a low risk of bias. The meta-analysis demonstrated that MSC therapy was related to a significantly lower mortality rate (OR 0.29, 95% CI 0.22–0.38, P < 0.001). Subgroup analyses performed based on the MSC injection dose (< 1.0 × 106 cells, OR = 0.33, 95% CI 0.20–0.56, P < 0.001; 1.0 × 106 cells, OR = 0.24, 95% CI 0.16–0.35, P < 0.001) and injection time (< 1 h, OR = 0.24, 95% CI 0.13–0.45, P < 0.001; 1 h, OR = 0.28, 95% CI 0.17–0.46, P < 0.001) demonstrated that treatment with MSCs significantly reduced the mortality rate of animals with sepsis. This up-to-date meta-analysis showed a connection between MSC therapy and lower mortality in sepsis animal models, supporting the potential therapeutic effect of MSC treatment in future clinical trials. The results in this study contradict a previous meta-analysis with regards to the ideal dose of MSC therapy. Thus, further research is required to support these findings.Keywords
Other Versions
Funding Information
- the Provincial Ministry Co-construction Project from the Medical Scientific and Technological Research Program of Henan Province (SBGJ2018020)
- the Scientific and Technological Innovation Leaders in Central Plains (194200510017)
- the Science and Technology people-benefit project of Zhengzhou (2019KJHM0001)
This publication has 53 references indexed in Scilit:
- Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndromeBMC Immunology, 2014
- Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligationJournal of Translational Medicine, 2012
- Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in ratsJournal of Inflammation, 2012
- Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneityResearch Synthesis Methods, 2010
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- The case of the misleading funnel plotBMJ, 2006
- Pluripotency of mesenchymal stem cells derived from adult marrowNature, 2002
- Multilineage Potential of Adult Human Mesenchymal Stem CellsScience, 1999